A multicentric pharmacovigilance study: Collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

Agnese Gugliandolo, Federica Longo, Maria Giovanna Marrosu, Giovanni Luigi Mancardi, Ilaria Gandoglia, Maurizio Melis, Fabrizio Lo Giudice, Placido Bramanti, Emanuela Mazzon

Research output: Contribution to journalArticle

Abstract

Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions. Patients and methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months. Results: We received a total of 411 adverse reactions, of which 84.18% were expected and only 15.82% were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild–moderate adverse reactions. Conclusion: Our results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.

Original languageEnglish
Pages (from-to)1765-1788
Number of pages24
JournalTherapeutics and Clinical Risk Management
Volume14
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Pharmacovigilance
multiple sclerosis
Relapsing-Remitting Multiple Sclerosis
Drug-Related Side Effects and Adverse Reactions
drug
Pharmaceutical Preparations
Safety
Injections
Drug Evaluation
Intravenous Administration
Multiple Sclerosis
Monitoring
Therapeutics
monitoring
evaluation

Keywords

  • Adverse drug reaction
  • Disease-modifying therapy
  • Pharmacovigilance
  • Relapsing-remitting multiple sclerosis
  • Safety

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

A multicentric pharmacovigilance study : Collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. / Gugliandolo, Agnese; Longo, Federica; Marrosu, Maria Giovanna; Mancardi, Giovanni Luigi; Gandoglia, Ilaria; Melis, Maurizio; Giudice, Fabrizio Lo; Bramanti, Placido; Mazzon, Emanuela.

In: Therapeutics and Clinical Risk Management, Vol. 14, 01.01.2018, p. 1765-1788.

Research output: Contribution to journalArticle

Gugliandolo, Agnese ; Longo, Federica ; Marrosu, Maria Giovanna ; Mancardi, Giovanni Luigi ; Gandoglia, Ilaria ; Melis, Maurizio ; Giudice, Fabrizio Lo ; Bramanti, Placido ; Mazzon, Emanuela. / A multicentric pharmacovigilance study : Collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. In: Therapeutics and Clinical Risk Management. 2018 ; Vol. 14. pp. 1765-1788.
@article{5f79e11bab41467d8663b0a9aca61dbd,
title = "A multicentric pharmacovigilance study: Collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients",
abstract = "Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions. Patients and methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months. Results: We received a total of 411 adverse reactions, of which 84.18{\%} were expected and only 15.82{\%} were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild–moderate adverse reactions. Conclusion: Our results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.",
keywords = "Adverse drug reaction, Disease-modifying therapy, Pharmacovigilance, Relapsing-remitting multiple sclerosis, Safety",
author = "Agnese Gugliandolo and Federica Longo and Marrosu, {Maria Giovanna} and Mancardi, {Giovanni Luigi} and Ilaria Gandoglia and Maurizio Melis and Giudice, {Fabrizio Lo} and Placido Bramanti and Emanuela Mazzon",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/TCRM.S174864",
language = "English",
volume = "14",
pages = "1765--1788",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A multicentric pharmacovigilance study

T2 - Collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

AU - Gugliandolo, Agnese

AU - Longo, Federica

AU - Marrosu, Maria Giovanna

AU - Mancardi, Giovanni Luigi

AU - Gandoglia, Ilaria

AU - Melis, Maurizio

AU - Giudice, Fabrizio Lo

AU - Bramanti, Placido

AU - Mazzon, Emanuela

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions. Patients and methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months. Results: We received a total of 411 adverse reactions, of which 84.18% were expected and only 15.82% were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild–moderate adverse reactions. Conclusion: Our results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.

AB - Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions. Patients and methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months. Results: We received a total of 411 adverse reactions, of which 84.18% were expected and only 15.82% were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild–moderate adverse reactions. Conclusion: Our results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.

KW - Adverse drug reaction

KW - Disease-modifying therapy

KW - Pharmacovigilance

KW - Relapsing-remitting multiple sclerosis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85058467448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058467448&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S174864

DO - 10.2147/TCRM.S174864

M3 - Article

AN - SCOPUS:85058467448

VL - 14

SP - 1765

EP - 1788

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -